The mRNA technology behind Moderna’s Covid vaccine reaches the flu

The mFlusiva vaccine for older people is the first made with the mRNA platform key to ending the coronavirus pandemic The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, Moderna, the manufact

In today's Pharmalittle newsletter: Moderna's mRNA flu shot approved, a death reported in a gene-editing trial in China, and more.

The flu shot, mFlusiva, was shown in a clinical trial to be up to 27 percent more effective than a standard flu jab

The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic

The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic

New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine  AP News

The Food and Drug Administration (FDA) late Wednesday approved the nation’s first mRNA flu vaccine, manufactured by drugmaker Moderna.  The agency approved the shot for two separate age groups; people age 50 to 64, and for 65 years and older. Moderna said it will conduct a postmarket clinical trial to confirm the effec

After refusing to even review it, the FDA has approved Moderna's mRNA seasonal flu vaccine.

FDA Approves First mRNA Flu Vaccine For Older Adults  Forbes

The Food and Drug Administration approved Moderna's mRNA seasonal flu vaccine on Wednesday.

The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced.

FDA approves first mRNA-based flu vaccine  CNN

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Process  WSJ

The agency had initially refused to even review the application but reversed course after a public outcry.

The trial, backed by up to $50 million from CEPI, comes as the Congo outbreak surpasses 3,700 confirmed cases and 1,600 deaths

Canada is now the second country to authorize a Phase I clinical trial for a Bundibugyo virus vaccine candidate after the U.K., according to federal officials in a news release.